GLP-3

Name: GLP-3
SKU: RT10
Price: 69.99 USD
Availability: InStock

2381089-83-2

Triple receptor agonist reference compound for metabolic-pathway research.

Mass

Price

~~$69.99~~$52.49

Quantity

25% off applied automatically with code HALO25.

Bundle and save

The 25% sitewide code is already on your cart. Bulk pricing replaces it when it beats it, with nothing to enter either way. Free U.S. shipping over $100.

Request COA

Free U.S. shipping over $100
Replacement protection included

Lost, stolen or damaged in transit? One replacement per order, on us.
Overnight shipping available

Pick your speed at checkout
Secure checkout

Release standard

99%+

Minimum purity by HPLC for every compound lot released.

Analyses per lot: 2
Methods: HPLC · MS
Laboratory: Independent

Molecular profile

CAS number: 2381089-83-2
Type: Triple receptor agonist peptide, 39 residues
Catalogue number: RT10
Nominal mass: 10 mg

Storage and handling

Appearance: Lyophilized powder
Solubility: Soluble in water
Storage: -20 °C, sealed and protected from light
Reconstituted: Refrigerate at 2-8 °C, use promptly
Classification: Laboratory research use only

Overview

GLP-3 is a single-chain synthetic peptide engineered to engage three distinct receptor targets: the glucose-dependent insulinotropic polypeptide (GIP) receptor, the glucagon-like peptide-1 (GLP-1) receptor, and the glucagon receptor. That triple-agonist profile is what makes it a reference compound in preclinical metabolic work.

In laboratory settings it is used to examine incretin receptor signaling, energy-balance regulation, and adipose tissue response in cellular and preclinical models. The multi-receptor profile makes it a practical comparator against single- and dual-agonist peptides.

Each vial contains 10 mg of lyophilized peptide, sealed for laboratory use. This material is supplied strictly for in-vitro research and laboratory experimentation and is not for human or veterinary use of any kind.

Documented research areas

Incretin receptor signaling (GIP / GLP-1 / glucagon receptor pathways)
Energy balance and metabolic-rate regulation in preclinical models
Adipose tissue biology and lipid metabolism studies
Comparative pharmacology versus single- and dual-agonist peptides

Certificate of analysis

Available on request

Each lot is released against an HPLC purity result and a mass-spectrometry identity confirmation. Tested by an independent laboratory in Los Angeles, CA. Send us your lot number and we'll email that lot's report.

Catalog: RT10
Release standard: ≥ 99% purity

Request the certificate

Usually sent the same business day.

Peer-reviewed literature

Selected published research on this compound

Independent, peer-reviewed work describing laboratory and clinical study of this compound. Listed so the research context on this page can be read at the source rather than taken on our word. These are not claims about this product.

01

New England Journal of Medicine 2023

Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial

Jastreboff AM, Kaplan LM, Frías JP, et al.
02

The Lancet 2023

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial

Rosenstock J, Frias J, Jastreboff AM, et al.